Cargando…

Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR

Cellular mesenchymal–epithelial transition factor (c-Met), an oncogenic transmembrane receptor tyrosine kinase (RTK), plays an essential role in cell proliferation during embryo development and liver regeneration. Thioredoxin reductase (TrxR) is overexpressed and constitutively active in most tumors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jinhui, Chen, Li, Lu, Zhonghui, Yao, Han, Hu, Yunfei, Feng, Luanqi, Pang, Yanqing, Wu, Jia-Qiang, Yu, Zhiling, Chen, Wen-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921947/ https://www.ncbi.nlm.nih.gov/pubmed/36770971 http://dx.doi.org/10.3390/molecules28031304

Ejemplares similares

To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors
por: Busker, Sander, et al.
Publicado: (2020)

Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity
por: Lei, Hong, et al.
Publicado: (2018)

TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport
por: Zhang, Yushuo, et al.
Publicado: (2017)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
por: Wang, Sicong, et al.
Publicado: (2023)

Selenium-ruthenium complex blocks H1N1 influenza virus-induced cell damage by activating GPx1/TrxR1
por: Li, Yinghua, et al.
Publicado: (2023)

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors
por: Xia, Yiqun, et al.
Publicado: (2021)

Sec-containing TrxR1 is essential for self-sufficiency of cells by control of glucose-derived H(2)O(2)
por: Peng, X, et al.
Publicado: (2014)

Changes of 8-OHdG and TrxR in the Residents Who Bathe in Radon Hot Springs
por: Yanxiao, Gao, et al.
Publicado: (2019)

Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells
por: Wu, Peng, et al.
Publicado: (2020)

Plasma and Synovial Fluid TrxR Levels are Correlated With Disease Risk and Severity in Patients With Rheumatoid Arthritis
por: Xie, Zhijun, et al.
Publicado: (2016)

MiR-23-TrxR1 as a novel molecular axis in skeletal muscle differentiation
por: Mercatelli, Neri, et al.
Publicado: (2017)

Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death
por: Busker, S., et al.
Publicado: (2020)

DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1‐mediated antioxidant effects
por: Rong, Yefei, et al.
Publicado: (2020)

Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk
por: Fan, Cun-dong, et al.
Publicado: (2017)

Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
por: Zhang, Qianqian, et al.
Publicado: (2019)

Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells
por: Chen, Xi, et al.
Publicado: (2018)

Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2021)

Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo
por: Fan, C, et al.
Publicado: (2014)

Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in TP53 mutant pancreatic tumors
por: Acedo, Pilar, et al.
Publicado: (2019)

Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy
por: Jovanović, Mirna, et al.
Publicado: (2020)

Mitochondrial TrxR2 regulates metabolism and protects from metabolic disease through enhanced TCA and ETC function
por: Chocron, E. Sandra, et al.
Publicado: (2022)

Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
por: Grädler, Ulrich, et al.
Publicado: (2023)

Corrigendum: Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
por: Zhang, Qianqian, et al.
Publicado: (2022)

Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells
por: He, Wei, et al.
Publicado: (2019)

Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
por: Galassi, Rossana, et al.
Publicado: (2021)

Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation
por: Chen, Weiqian, et al.
Publicado: (2016)

Retraction Note: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2022)

Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis
por: De Franco, Michele, et al.
Publicado: (2022)

miR-125a Suppresses TrxR1 Expression and Is Involved in H(2)O(2)-Induced Oxidative Stress in Endothelial Cells
por: Chen, Fangjie, et al.
Publicado: (2018)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
por: Pudelko, Linda, et al.
Publicado: (2020)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Alantolactone promotes ER stress‐mediated apoptosis by inhibition of TrxR1 in triple‐negative breast cancer cell lines and in a mouse model
por: Yin, Changtian, et al.
Publicado: (2019)

PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation
por: Yin, Zhi-Xian, et al.
Publicado: (2017)

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
por: Xu, Lianrong, et al.
Publicado: (2019)

The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer
por: Chen, Gong, et al.
Publicado: (2017)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

A possible role for selenoprotein glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: our experience in thyroid surgery
por: Metere, Alessio, et al.
Publicado: (2018)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mve61thrtmljpo3r4gkpqf6los